心血管病学进展2024,Vol.45Issue(1) :31-34.DOI:10.16806/j.cnki.issn.1004-3934.2024.01.009

肺动脉高压的非药物治疗

Non-Drug Treatment of Pulmonary Hypertension

滕菲 南景龙
心血管病学进展2024,Vol.45Issue(1) :31-34.DOI:10.16806/j.cnki.issn.1004-3934.2024.01.009

肺动脉高压的非药物治疗

Non-Drug Treatment of Pulmonary Hypertension

滕菲 1南景龙1
扫码查看

作者信息

  • 1. 内蒙古自治区人民医院心内科,内蒙古 呼和浩特 010000
  • 折叠

摘要

肺动脉高压(PH)是以肺动脉血流动力学异常为特征的一组临床综合征.其发病机制涉及多学科、系统和通路,治疗亦是多方面、多角度的.目前PH的治疗以药物治疗和非药物治疗为主.PH药物治疗的重点是动脉型PH和慢性血栓栓塞性PH,随着靶向药物(如内皮素受体抑制剂、前列环素类、磷酸二酯酶V型抑制剂和可溶性鸟苷酸环化酶激动剂)的进展,患者预后有所改善,但5年生存率仍不超过70%.因此,可将非药物治疗方式作为PH治疗的另一选择.现就PH的非药物治疗做一综述.

Abstract

Pulmonary hypertension(PH)is a group of clinical syndromes characterized by abnormal pulmonary hemodynamics.Its pathogenesis involves multiple disciplines,multiple systems and multiple pathways so that its treatment is multi-faceted and multi-angle.At present,the treatment of PH mainly involves drug treatment and non-drug treatment.The focus of drug treatment of PH are pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension.Even if the prognosis of PH patients is significantly improved by using targeted drugs such as endothelin receptor inhibitor,prostaglandin,phosphodiesterase type 5 inhibitor and soluble guanoylate cyclase agonist,the 5-year survival rate is still not more than 70%.Therefore,non-drug treatment can be used as another option for PH treatment.This article reviews the non-drug treatment of PH.

关键词

肺动脉高压/非药物治疗/临床治疗

Key words

Pulmonary hypertension/Non-drug treatment/Clinical treatment

引用本文复制引用

出版年

2024
心血管病学进展
成都市心血管病研究所,成都市第三人民医院

心血管病学进展

CSTPCD
影响因子:0.932
ISSN:1004-3934
参考文献量37
段落导航相关论文